Pharmaceuticals
Cistto Launches the "Humanized Anti-Aging Global Scientist Alliance" in China, Empowering Products with Cutting-Edge Science
LOS ANGELES, Nov. 25, 2024 /PRNewswire/ -- As an emerging brand specializing in sensitive skin repair, Cistto is grounded in skin science and committed to advancing skin health through the latest dermatological breakthroughs and cutting-edge biotechnology. Cistto is steadfast in its promise to de...
2024-11-25 23:00
2596
Food Allergy: LongBio's LP-003 achieves its fourth IND approval
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA,China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-IgE antibody, to begin a clinical trial for the treatment ...
2024-11-25 22:00
3394
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts
ITASCA, Ill., Nov. 25, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand American Bear Logistics ("ABL"), announces th...
2024-11-25 21:30
2690
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
* HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. * No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. * PK results support once a day dosing. ROCKVILLE, Md. and SEOUL,...
2024-11-25 20:00
2733
Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy
Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) un...
2024-11-25 09:30
4052
Hankyung.com introduces: MecKare, Leading the AI-powered Innovation in Health Monitoring Solution
- Leading efficient care management for the elderly with unimpeded smartcare
https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png
2024-11-23 21:00
4242
BGM Group Welcomes Guilin Pharma for On-site Audit and Partnership Development
CHENGDU, China, Nov. 22, 2024 /PRNewswire/ -- On November 19, Qilianshan Pharmaceutical Co., Ltd. (Qilian Pharma), a subsidiary of BGM Group Ltd, welcomed a team of experts from Guilin Pharmaceutical Co., Ltd. (Guilin Pharma), including Quality Assurance Engineer Ms. Shen and Technical Manager M...
2024-11-22 21:30
3537
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
HONG KONG, Nov. 22, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination...
2024-11-22 19:34
2789
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, announced today that findings from a ph...
2024-11-22 10:15
2707
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of itsGenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference inS...
2024-11-21 23:46
3009
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024
SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will part...
2024-11-21 18:00
2136
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthr...
2024-11-21 15:09
6943
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation
This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswi...
2024-11-21 13:01
2944
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
VANCOUVER, BC, Nov. 20, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, Calif.-based genomic sequencer manufacturer, today announced at the 2024 Association for Molecular Pathology (AMP) Annual Meeting & Expo the launch of its mpox (MPXV) virus amplicon sequencing panel, part of its sequencin...
2024-11-21 01:01
2301
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...
2024-11-20 22:00
3246
Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- On November 13th, a high-level delegation from the Alfasigma Group, led by Mr. Andriy Samoylovych, Chief Commercial Officer of Global Growth Markets, and Ms.Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou...
2024-11-20 10:38
2600
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...
2024-11-20 07:20
2519
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...
2024-11-19 21:26
3040
Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity
* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...
2024-11-19 21:00
2840
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
3873
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 291 media titles]
2026-09-24 10:30
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 278 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 274 media titles]
2026-09-25 14:45
Most Read
The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week
2026-09-19 09:00
7370
iScreen Expands iOS 27 Customization With New Extra-Large Widget Experiences, iPhone Duo Theme Support and AI-Powered Home Screen Design
2026-09-19 06:00
7339
